Tradestie Institutional Equity Comparison Engine · Market Close Feb 06, 2026

AKRO vs GBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)

AKRO Overall Winner 6-Pillar Tally: AKRO 3 – 1 GBIO (2 Tie) Matrix Metrics: AKRO 7 – 2 GBIO

As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs GBIO
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
TTM Revenue $15M
Forward P/E 7.9x
Beta / 30D Vol 0.80β · 26% Vol
Unified Composite Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $5.61 · SMA50: $5.49

6-Pillar Scorecard Institutional Category Breakdown (AKRO 3 – 1 GBIO)

Columns: Metric · AKRO · GBIO
1. Valuation Multiples GBIO
Forward P/E N/M 7.9x
Trailing P/E N/M 7.9x
PEG Ratio N/M N/M
EV / Revenue N/M 2.5x
2. Growth & Scale AKRO
Revenue Growth (YoY) +0.0% -78.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $15M
Market Cap $4.5B $38.7M
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin 0.0% -2020.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -34.5% -80.8%
4. Balance Sheet & Cash Flow AKRO
Cash Generation (TTM) N/A -$76M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $7.51 Book/Sh · -80.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 7.3% (30th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (7) vs GBIO (2)
Institutional Metric AKRO GBIO Criterion Row Edge
Market Capitalization
Scale
$4.5B $38.7M Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M 7.9x Lower Multiple GBIO
Forward P/E Ratio
Valuation
N/M 7.9x Lower Multiple GBIO
Revenue Growth (YoY)
Growth
+0.0% -78.9% Higher Growth AKRO
Operating Margin (TTM)
Profitability
0.0% -2020.0% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-34.5% -80.8% Higher ROE AKRO
52-Week Range Position
Momentum
90% ($21–$58) 62% ($0–$8) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 0.80β · 26% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 58.8 / 100 (HOLD) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $15M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) -$76M EBITDA ($7.51 Book/Sh · -80.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GBIO +4.01 pp
AKRO: +1.37% · GBIO: +5.38%
3M Horizon AKRO +36.46 pp
AKRO: +22.48% · GBIO: -13.98%
6M Horizon GBIO +1229.26 pp
AKRO: -0.11% · GBIO: +1229.15%
1Y Horizon AKRO +31.37 pp
AKRO: -5.06% · GBIO: -36.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs GBIO. Trailing 12-month operating profitability (AKRO 0.0% vs GBIO -2020.0%) and valuation multiples (AKRO N/M vs GBIO 7.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
GBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15M
Gross MarginN/A
Op. Margin-2020.0%
ROE / Fwd P/E-80.8% · 7.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs GBIO Key Questions & Quantitative Answers

As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin). Technically, AKRO sits in a Markup phase (RSI 67.3, UNCLASSIFIED options structure) and GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure).

AKRO leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GBIO at -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $15M for GBIO. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GBIO.

GBIO screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus GBIO (-80.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 06, 2026. For educational research only; not investment advice.